RANI Stock Analysis: Buy, Sell, or Hold?
RANI - Rani Therapeutics Holdings, Inc. Class A Common Stock
$0.68
0.03 (4.31%)
▲
5d:
-2.31%
30d:
-10.93%
90d:
-19.14%
BUY
MODERATE Confidence
Analysis Updated: Jul 15, 2026 12:00 AM ET
Earnings: Aug 06, 2026
20d
Get Alerted When RANI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RANI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RANI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RANI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RANI is currently trading at $0.68, which is considered oversold relative to its 30-day fair value range of $0.70 to $0.80.
Technical Outlook: Technically, RANI is in a strong downtrend. Immediate support is located at $0.61, while resistance sits at $0.83. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: RANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+1007.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RANI is in a strong downtrend. Immediate support is located at $0.61, while resistance sits at $0.83. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: RANI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.50 (+1007.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.70 -
$0.80
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 1007.8% below Wall St target ($7.50)
Trading Range Analysis
30-Day Trading Range
$0.70 -
$0.80
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.61
Resistance Level
$0.83
Current Trend
Strong Downtrend
Technical data as of
Jul 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.12
Wall Street Target
$7.50
(+1007.8%)
Revenue Growth (YoY)
893.0%
Share & Embed Analysis
Last updated: July 15, 2026 9:56 PM ET
Data refreshes hourly during market hours. Next update: 10:56 PM
Data refreshes hourly during market hours. Next update: 10:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RANI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 55 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 41 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
